- No public price. The homepage shows none.
- Not disclosed
- Not disclosed
- —
- —
- US
Radiology
DeepHealth
by RadNet / DeepHealth, Inc. · US
Imaging AI from RadNet's DeepHealth: mammography (Saige-Dx, Saige-Density), breast arterial calcification, prostate, lung, bone and chest X-ray.
On this page
36/100Competitive
- Regulatory & Compliance18/28
FDA cleared (18 K-numbers on record)
- Clinical Integration0/26
No EHR integrations listed
- Evidence Strength7.3/26
1 peer-reviewed paper
- Vendor & Market12/18
Top-tier funding and adoption
- Sentiment & Transparency2.5/14
Pricing on request, no public amounts
▸ Show all 11 dimensions▾ Hide dimension detail
- FDA clearance18/18
FDA cleared (18 K-numbers on record)
- HIPAA / SOC2 / BAA0/10
No public HIPAA/SOC2/BAA attestation
- EHR integrations (count)0/14
No EHR integrations listed
- Top-3 EHR coverage (Epic / Oracle / Athena)0/8
None of the top-3 EHRs covered
- Bidirectional write-back0/4
No bidirectional write-back documented
- Peer-reviewed papers7/18
1 peer-reviewed paper
- RCT / meta-analysis / systematic review0/8
No RCT, meta-analysis, or systematic review
- Funding & adoption signal12/12
Top-tier funding and adoption
- Years in market0/6
Founded year not recorded
- Clinician sentiment (Reddit)0/9
No clinician sentiment data available
- Pricing transparency3/5
Pricing on request, no public amounts
World's largest after Gleamer acquisition (March 2026).
RadNet-owned. CXR, mammography, CT, MRI. ~$140M ARR projected EOY 2026. Spans CV + onc + neuro.
Bottom line
DeepHealth is the radiology AI arm of RadNet, the US outpatient imaging chain, and RadNet has acquired its way to a broad portfolio: mammography AI, prostate, lung, brain, bone and chest X-ray software, plus a cloud imaging platform. Breast screening is the core, with ten FDA records under the DeepHealth name for Saige-Dx, Saige-Density, Saige-Q triage, a breast arterial calcification (BAC) tool and TechLive. It suits imaging groups and health systems that want one vendor across modalities. Independent proof of benefit is thin, since the main reader study came from the vendor's own employees.
Who is behind it?
DeepHealth, Inc. is a subsidiary of RadNet (Nasdaq: RDNT) with an address at 212 Elm Street, Somerville, Massachusetts. Greg Sorensen and Bill Lotter founded it in 2015, per PitchBook and Radiology Business. RadNet announced the acquisition on March 11, 2020, for a reported $40 million or more.
The acquisition list since then is long:
- Quantib and Aidence in 2022 for nearly $100 million combined. Aidence's Veye Lung Nodules became DeepHealth Lung.
- Kheiron Medical Technologies on October 22, 2024, with terms undisclosed.
- iCAD, closed July 17, 2025, all stock, about $110.7 million per RadNet's 10-Q.
- Gleamer of Paris, announced March 2, 2026, for up to 230 million euros (about $269 million) in cash plus milestones.
RadNet calls DeepHealth the largest provider of radiology clinical AI solutions worldwide after the Gleamer deal, which is the company's own claim. It expects Gleamer annual recurring revenue near $30 million in 2026, and about a $5 million adjusted EBITDA loss from the deal that year.
What does it sell?
The homepage splits the portfolio into Enterprise Imaging (Diagnostic Suite, Operations Suite, TechLive and Reporting Pro) and Population Health (SmartMammo for breast, plus Prostate, Lung, Brain and Thyroid). DeepHealth OS is a cloud-native layer meant to unify clinical and operational data. Reporting Pro combines speech recognition, AI findings, measurements and quality assurance, and the prostate product is compatible with leading fusion biopsy systems. Gleamer adds BoneView, BoneMetrics and ChestView US.
For patients, RadNet's own centers offer AI mammography under the EBCD program at an extra fee.
What has the FDA cleared?
FDA's 510(k) database lists ten records under DeepHealth, Inc.:
- Saige-Dx: K220105 (May 12, 2022), K241747 (November 18, 2024), K243688 (version 3.1.0, December 19, 2024), K251873 (August 11, 2025) and K253825 (June 15, 2026).
- Saige-Density: K222275 (December 16, 2022) and K243705 (version 2.5.0, December 19, 2024).
- Saige-Q triage: K203517 (April 16, 2021).
- TechLive: K243703 (June 5, 2025).
- BAC software: K254131 (May 21, 2026).
iCAD and Gleamer carry separate applicant records. iCAD has ProFound AI (K191994, K203822) and ProFound Detection V4.0 (K240417, November 8, 2024). Gleamer has BoneView (K212365, K222176), BoneMetrics (K241593) and ChestView US (K241620, K252486 on September 9, 2026). Brain Health, Brain Age, LumbarMR, Prostate and TechLive hold CE marks, per the homepage. TechLive is listed on the AWS Marketplace.
What does the evidence say?
The best-known study is a Saige-Dx reader study in Radiology: AI with 18 readers and 240 cases. AUC rose from 0.87 to 0.93 with the AI, a gain of 0.08 for general radiologists and 0.05 for breast specialists. Its authors are DeepHealth employees, and the case set was retrospective and enriched, so it measures reader assistance on a curated sample and not screening outcomes. Public praise comes from RadNet and DeepHealth material, such as a quote from a breast imager at Lenox Hill Radiology.
What does it cost?
The only price in the public material is for patients: RadNet charges extra for AI mammography under EBCD. Software fees are not given anywhere in the public material.
How does it compare?
On breast arterial calcification, CureMetrix's cmAngio was cleared first (K232367, October 5, 2023), and DeepHealth followed with K254131 on May 21, 2026.
The verdict
DeepHealth has a long FDA record and now owns several formerly independent products. For an imaging group that wants breast, bone and chest AI under one contract, that breadth is the draw. The performance evidence is vendor authored and the portfolio is still being merged, so a group that wants independent proof first, or one product rather than a roadmap, should wait.
Editorial review last generated October 15, 2026. Synthesized from clinician sentiment, peer-reviewed coverage, and our editorial silo picks. Refined by hand where vendor facts change.
What it costs
All tiers are custom-quoted. The vendor does not publish per-provider list pricing.
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | — | — | No public price. The homepage shows none. |
Source: vendor pricing page. Last checked October 15, 2026.
What deploys cleanly
Carries FDA 510(k) (multiple), CE Mark (Mia, 2019, per DeepHealth page) per vendor documentation. Independent attestation review is the buyer's responsibility before clinical deployment.
What the literature says
1 peer-reviewed study indexed on PubMed evaluate DeepHealth in clinical contexts. The most relevant are shown below, ranked by editorial relevance score combining title match, study design, recency, and journal tier.
- Artificial intelligence (AI) to enhance breast cancer screening: protocol for population-based cohort study of cancer detection.
- Marinovich ML, Wylie E, Lotter W, et al.· BMJ Open· 2022
- Artificial intelligence (AI) algorithms for interpreting mammograms have the potential to improve the effectiveness of population breast cancer screening programmes if they can detect cancers, including interval cancers, without contributing substantially to overdiagnosis. Studies suggesting that AI has comparable or greater accuracy than radiologists commonly employ 'enriched' datasets in which cancer prevalence is higher than in population screening. Routine screening outcome metrics (cancer detection and recall rates) cannot be estimated from these datasets, and accuracy estimates ma…
Other radiology
See the full radiology ranking
Siemens Healthineers AI-Rad Companion
by Siemens Healthineers
AI-Rad Companion: Chest CT, Chest X-ray, Brain MR, Prostate MR and Organs RT (radiotherapy contouring) modules, delivered through teamplay.
No public price on the vendor page.|FDA 510(k) (multiple) / CE Mark (MDD/MDR. MDR status not verified)
GE HealthCare AI Suite
by GE HealthCare
Portfolio of separately cleared AI-enabled GE HealthCare devices and software, including AIR Recon DL, Sonic DL, Critical Care Suite, Caption AI and icobrain.
No public price. Products are sold with scanners or as scanner options, on enterprise quotes.|FDA 510(k) (multiple)
Aidoc
by Aidoc
Clinical AI platform (aiOS) with FDA-cleared triage, notification and quantification algorithms for radiology and neurovascular care.
Private offer only. No trial is stated.|FDA 510(k) (multiple) / EU MDR 2017/745
Viz.ai
by Viz.ai
Care coordination platform with FDA-cleared imaging AI for stroke, vascular and cardiac conditions.
No public price. Sold to health systems after a demo request.|FDA 510(k) (multiple) / FDA De Novo (ContaCT, Viz HCM)